Other substances

Maprotiline

A tetracyclic antidepressant.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
1
 AI-suggested references
0
 Clinical trials

General information

Maprotiline is a tetracyclic antidepressant which inhibits neuronal norepinephrine reuptake, manifests some anticholinergic activity, and does not affect monoamine oxidase activity. Maprotiline does not appear to impede the reuptake of serotonin. It is used for the treatment of depressive and anxiety disorders (DrugBank).

Maprotiline on PubChem
Maprotiline on Wikipedia

Marketed as

DEPRILEPT; LUDIOMIL; PSYMION

 

Structure image - Maprotiline

CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24

Supporting references

Link Tested on Impact factor Notes Publication date
Kinetic characterization and inhibitor screening for the proteases leading to identification of drugs against SARS-CoV-2
3CLpro PapainLpro Small molecule Enzyme assay In vitro 		in vitro enzyme assay; Vero E6 cells 4.92

The compound inhibited the SARS-CoV-2 Papain-like protease in a dose-dependent manner in vitro. It protected Vero E6 cells from viral infection with EC50 of 9.3 μM and SI of 3.4. It was determined to be active at the post-entry stage of infection.

 Feb/01/2021

AI-suggested references

Link Publication date
Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells.
Oct/29/2020
Export (.csv)